Loading organizations...
Key people at Tramway Venture Partners.
Tramway Venture Partners is a venture capital firm specializing in early-stage life science companies, targeting opportunities exploiting convergent technologies across physical sciences, information technology, life sciences, and healthcare. The firm invests in startups with strong intellectual property and clear market strategies, providing initial institutional funding, utilizing New Mexico's robust research and development infrastructure.
The firm's genesis stems from the insight that New Mexico, rich with national laboratories and research universities, presented an undervalued wellspring for life science innovation. Managing Partners Katie Rice and Chris Japp recognized potential to cultivate disruptive companies by connecting advanced technological capabilities with entrepreneurial talent within an overlooked market.
Tramway Venture Partners empowers early-stage life science and healthcare ventures with capital, strategic guidance, and network access. Its vision is to discover and build enduring companies in partnership with New Mexico's research institutions, fostering a vibrant entrepreneurial ecosystem. The firm aims to establish the region as a significant innovation hub.
Key people at Tramway Venture Partners.
Tramway Venture Partners has 3 tracked investments across 3 companies. The latest tracked deal is $2.5M Seed in Daisy Genomics in December 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 17, 2025 | Daisy Genomics | $2.5M Seed | — | Cottonwood Technology Fund, Wave Capital |
| Aug 6, 2024 | Nob Hill Therapeutics | $3.0M Series A | Tramway Venture Partners | — |
| Jan 1, 2024 | Circular Genomics | $8.0M Series A | Mountain Group Partners | Cottonwood Technology Fund, UNM Rainforest Innovations |